"Proglumide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
| Descriptor ID |
D011377
|
| MeSH Number(s) |
D12.125.068.330.700 D12.125.095.461.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Proglumide".
Below are MeSH descriptors whose meaning is more specific than "Proglumide".
This graph shows the total number of publications written about "Proglumide" by people in this website by year, and whether "Proglumide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proglumide" by people in Profiles.
-
Rabiee A, Gay MD, Shivapurkar N, Cao H, Nadella S, Smith CI, Lewis JH, Bansal S, Cheema A, Kwagyan J, Smith JP. Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis. Clin Pharmacol Ther. 2022 12; 112(6):1271-1279.
-
Gay MD, Cao H, Shivapurkar N, Dakshanamurthy S, Kallakury B, Tucker RD, Kwagyan J, Smith JP. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. Int J Mol Sci. 2022 Feb 08; 23(3).
-
Jaffe DB, Aitken PG, Nadler JV. The effects of cholecystokinin and cholecystokinin antagonists on synaptic function in the CA1 region of the rat hippocampal slice. Brain Res. 1987 Jul 07; 415(1):197-203.